Clinical Trial Update: Efficacy and Safety of Grass-SPIRE Registration Study [Phase 2, Phase 3]

View source ↗

Summary

Circassia Limited has withdrawn the Grass-SPIRE registration study, a Phase 2/3 trial, for rhinitis and conjunctivitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Conjunctivitis
• Rhinitis

Drugs mentioned

• Grass-SPIRE

Snippet

Sponsor: Circassia Limited | Conditions: Rhinitis, Conjunctivitis | Phase 2, Phase 3 | Status: WITHDRAWN